Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 4471 AL 4485

Opportunities and challenges in developing relevant animal models for Alzheimer's disease

De Felice FG, Munoz DP.

Ageing Res Rev. 2016 Mar;26:112-4. doi: 10.1016/j.arr.2016.01.006. Epub 2016 Jan 30.

Diagnostic Assessment and Management of Dysphagia in Patients with Alzheimer's Disease

Boccardi V, Ruggiero C, Patriti A, Marano L.

J Alzheimers Dis. 2016;50(4):947-55. doi: 10.3233/JAD-150931.

Gray matter volumes and treatment response of psychotic symptoms to risperidone in antipsychotic-naïve Alzheimer's disease patients

Lee YM, Park JM, Lee BD, Moon E, Jeong HJ, Chung YI, Kim JH, Kim HJ, Mun CW, Kim TH, Kim YH.

J Clin Psychiatry. 2016 Jan;77(1):e8-13. doi: 10.4088/JCP.14m09740.

Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy

Wattmo C, Minthon L, Wallin ÅK.

Alzheimers Res Ther. 2016 Feb 17;8:7. doi: 10.1186/s13195-016-0174-1.

Editorial: Translational Alzheimer's Disease Research

Huang Y, Lahiri DK.

Curr Alzheimer Res. 2016;13(3):214. doi: 10.2174/156720501303160217102238.

Donepezil 23 mg in Asian patients with moderate-to-severe Alzheimer's disease

Han SH, Lee JH, Kim SY, Park KW, Chen C, Tripathi M, Dash A, Kubota N.

Acta Neurol Scand. 2017 Feb;135(2):252-256. doi: 10.1111/ane.12571. Epub 2016 Feb 29.

Evaluation of a mobile team dedicated to behavioural disorders as recommended by the Alzheimer Cooperative Valuation in Europe joint action: observational cohort study

Krolak-Salmon P, Roubaud C, Finne-Soveri H, Riolacci-Dhoyen N, Richard G, Rouch I, Leperre-Desplanques A, Dauphinot V.

Eur J Neurol. 2016 May;23(5):979-88. doi: 10.1111/ene.12975. Epub 2016 Mar 6.

Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease

Pasquier F, Sadowsky C, Holstein A, Leterme Gle P, Peng Y, Jackson N, Fox NC, Ketter N, Liu E, Ryan JM; ACC-001 (QS-21) Study Team.

J Alzheimers Dis. 2016;51(4):1131-43. doi: 10.3233/JAD-150376.

Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study

Florian H, Meier A, Gauthier S, Lipschitz S, Lin Y, Tang Q, Othman AA, Robieson WZ, Gault LM.

J Alzheimers Dis. 2016;51(4):1237-47. doi: 10.3233/JAD-150978.

Significant cognitive improvement with cholinesterase inhibition in AD with cerebral amyloid angiopathy

Paterson RW, Abdi Z, Haines A, Schott JM.

Clin Neurol Neurosurg. 2016 May;144:64-6. doi: 10.1016/j.clineuro.2016.02.036. Epub 2016 Mar 3.

Transcranial direct current stimulation as a memory enhancer in patients with Alzheimer's disease: a randomized, placebo-controlled trial

Bystad M, Grønli O, Rasmussen ID, Gundersen N, Nordvang L, Wang-Iversen H, Aslaksen PM.

Alzheimers Res Ther. 2016 Mar 23;8(1):13. doi: 10.1186/s13195-016-0180-3.

Rivastigmine Patch in Chinese Patients with Probable Alzheimer's disease: A 24-week, Randomized, Double-Blind Parallel-Group Study Comparing Rivastigmine Patch (9.5 mg/24 h) with Capsule (6 mg Twice Daily)

Zhang ZX, Hong Z, Wang YP, He L, Wang N, Zhao ZX, Zhao G, Shang L, Weisskopf M, Callegari F, Strohmaier C.

CNS Neurosci Ther. 2016 Jun;22(6):488-96. doi: 10.1111/cns.12521. Epub 2016 Mar 25.

Neuroimaging in Alzheimer's disease: preclinical challenges toward clinical efficacy

Dustin D, Hall BM, Annapragada A, Pautler RG.

Transl Res. 2016 Sep;175:37-53. doi: 10.1016/j.trsl.2016.03.005. Epub 2016 Mar 12.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias